Stage
No active trials
Next date
None yet
Trials
0 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Gynecologic Neoplasms, Epithelial Ovarian Cancer, Metastatic Castration-resistant Prostate Cancer, Small Cell Lung Cancer, Uveal Melanoma, Ovarian Clear Cell Carcinoma, Non-Hodgkin Lymphoma, Advanced Malignancies and 6 more
- Main trialPhase 1/2
- “The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in Advanced Gynecological Malignancies with a Known ARID1A Mutation and PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer.”In the company’s words, NCT04493619 on ClinicalTrials.gov
Other drugs for Epithelial Ovarian Cancer
- OregovomabCanariaBio Inc. · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- Torvutatug samrotecanAstraZeneca · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- Trastuzumab deruxtecanDaiichi Sankyo · AstraZeneca · Phase 3
- BL-M07D1Sichuan Baili (Biokin, SystImmune) · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Terminated | 25 Apr 2022 | PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer | |
| Phase 1/2Terminated | 24 May 2022 | PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | |
| Phase 1Completed | 7 Jun 2021 | A Study of PLX2853 in Advanced Malignancies. | |
| Phase 1Completed | 30 Jun 2021 | A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026